Bacterial Infections
Welcome,         Profile    Billing    Logout  
 127 Companies   123 Products   123 Products   59 Mechanisms of Action   6 Trials   3245 News 


«12...1011121314151617181920...6566»
  • ||||||||||  ceftriaxone / Generic mfg.
    Trial completion:  PLEASE: Persistent Lyme Empiric Antibiotic Study Europe (clinicaltrials.gov) -  Sep 8, 2016   
    P4,  N=280, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients (clinicaltrials.gov) -  Sep 2, 2016   
    P4,  N=114, Completed, 
    Recruiting --> Active, not recruiting | N=480 --> 69 | Trial primary completion date: Feb 2018 --> Aug 2016 Enrolling by invitation --> Completed | N=200 --> 114 | Trial primary completion date: Dec 2016 --> Sep 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  PseudIgY: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (clinicaltrials.gov) -  Sep 2, 2016   
    P1/2,  N=14, Completed, 
    Enrolling by invitation --> Completed | N=200 --> 114 | Trial primary completion date: Dec 2016 --> Sep 2016 Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
    Trial primary completion date:  Efficacy of Rifaximin in Preventing Campylobacteriosis (clinicaltrials.gov) -  Sep 1, 2016   
    P2/3,  N=28, Active, not recruiting, 
    Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012 Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  Trial completion, Enrollment change:  Gastric and Duodenal Microbiota in Dyspeptic Subjects (clinicaltrials.gov) -  Aug 31, 2016   
    P=N/A,  N=121, Completed, 
    Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a Recruiting --> Completed | N=200 --> 121
  • ||||||||||  Shanchol (oral cholera vaccine) / Sanofi
    Trial primary completion date:  ICVB: Introduction of Cholera Vaccine in Bangladesh (clinicaltrials.gov) -  Aug 31, 2016   
    P=N/A,  N=240000, Recruiting, 
    Recruiting --> Completed | N=200 --> 121 Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  PnuBioVax (PBV) / ImmunoBiology
    Trial primary completion date:  A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax (clinicaltrials.gov) -  Aug 31, 2016   
    P1,  N=36, Active, not recruiting, 
    Trial primary completion date: Mar 2017 --> Jun 2017 Trial primary completion date: May 2016 --> Sep 2016
  • ||||||||||  Trial completion, Enrollment change:  Validity of Patient-Collected Wet Mounts (clinicaltrials.gov) -  Aug 26, 2016   
    P=N/A,  N=77, Completed, 
    Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Completed | N=40 --> 77
  • ||||||||||  Shanchol (oral cholera vaccine) / Sanofi
    Trial completion:  A Study of Two Doses of Oral Cholera Vaccine (Shanchol (clinicaltrials.gov) -  Aug 24, 2016   
    P3,  N=336, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  rifampicin / Generic mfg.
    Trial completion, Trial primary completion date:  Trial of High-Dose Rifampin in Patients With TB (clinicaltrials.gov) -  Aug 19, 2016   
    P2,  N=180, Completed, 
    Trial primary completion date: Apr 2017 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2016
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis (clinicaltrials.gov) -  Aug 19, 2016   
    P=N/A,  N=19, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Completed | N=25 --> 19 | Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: May 2016 --> Dec 2015
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Epidemiology of Helicobacter Pylori Infection Among Shanghai Children (clinicaltrials.gov) -  Aug 16, 2016   
    P=N/A,  N=1997, Completed, 
    N=500 --> 399 Recruiting --> Completed | N=1500 --> 1997 | Trial primary completion date: Jun 2015 --> Sep 2015
  • ||||||||||  TOL-463 / Toltec Pharma
    New P2 trial:  TOL-463 Phase 2 Study for Vaginitis (clinicaltrials.gov) -  Aug 15, 2016   
    P2,  N=90, Recruiting, 
  • ||||||||||  Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date, Adherence:  Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods (clinicaltrials.gov) -  Aug 12, 2016   
    P=N/A,  N=38, Active, not recruiting, 
    Recruiting --> Completed | N=1500 --> 1997 | Trial primary completion date: Jun 2015 --> Sep 2015 Not yet recruiting --> Active, not recruiting | N=600 --> 38 | Initiation date: May 2016 --> Jan 2015 | Trial primary completion date: Jan 2017 --> Jan 2016
  • ||||||||||  apremilast / Generic mfg.
    Enrollment open, Trial initiation date:  Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) -  Aug 9, 2016   
    P2,  N=20, Recruiting, 
    N=400 --> 600 | Trial primary completion date: Jan 2017 --> Jan 2019 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jul 2016